AKT1 and gastric cancer: El-Rifai and colleagues19 demonstrated that DARPP-32 promotes cell survival and gefitinib resistance in gastric cancer cells by stimulating EGFR phosphorylation and activating phosphatidylinositol 3-kinase/Akt signaling.